clairop

How Long Do Crohn's Biologics Take to Work?

Biologics for Crohn's are usually judged at weeks 12 to 14, not week 2. Trial and label timelines by drug, what counts as response, and how to log it.

Clairop Team18 min read

Photo: Land O'Lakes, Inc. / Unsplash

The short answer

Most Crohn's biologics are judged after the induction doses, around weeks 12 to 14, though some people feel better within days and others need months. Trials score each drug at set weeks, and labels for infliximab and vedolizumab both point to week 14. A weekly symptom log gives your gastroenterologist something concrete to judge it by.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Most Crohn's biologics take weeks, not days, to show their full effect, and trials and prescribing labels judge them after the induction doses, usually between weeks 6 and 14. Some people feel better within days, others need three months or more. A biologic is a lab-made antibody medicine given by infusion or injection to calm inflammation, and your gastroenterologist decides when it has had a fair trial.

How long do Crohn's biologics take to work?

Expect a range. Some people notice less pain or fewer stools within days or a few weeks, but the trials that earned these drugs their licences scored them after the induction doses, at weeks 4, 6 or 12 depending on the drug. Two US labels, for infliximab and vedolizumab, refer to week 14 as the point where a prescriber reassesses (Remicade label; Entyvio label).

That matches what people in r/CrohnsDisease describe. In three recent threads asking about timelines (how long for your biologic to work, how long did your medication take, time to remission), the answers run from "almost immediately" to "a couple of months" to "four to six months before the inflammation went down". A common rule of thumb in those threads is that something should be visible by week 12 to 16, and that if not, it is time to ask the gastroenterologist what is next. That rule of thumb is close to how the labels read, but it is a prompt to ask a question, not a decision to make alone. Thread experience is also not evidence: people with milder disease, people on steroids and people who had already failed other drugs all answer the same question differently.

The table below puts what is actually published side by side. Doses are left out on purpose, because your schedule is set by your team.

Drug (class)Induction schedule per US labelTrial's first scored pointWhat the trial foundLabel wording on assessing response
Infliximab (anti-TNF)Infusions at weeks 0, 2 and 6, then every 8 weeksWeek 2 response, week 30 remission (ACCENT I)58% responded within 2 weeks of one infusion"Patients who do not respond by Week 14 are unlikely to respond with continued dosing"
Adalimumab (anti-TNF)Two induction injections at weeks 0 and 2 in the trials, then maintenanceWeek 4 remission (CLASSIC I)36% in remission at week 4 on the best regimen, 12% on placeboLabel not verified for this article
Vedolizumab (integrin)Infusions at weeks 0, 2, then week 6Week 6 (GEMINI 2)14.5% in remission at week 6 versus 6.8% on placebo"Discontinue... in patients who do not show evidence of therapeutic benefit by Week 14"
Ustekinumab (IL-12/23)One infusion, first injection 8 weeks laterWeek 6 (UNITI)Response 34.3% versus 21.5% (after anti-TNF failure)No week cut-off found
Risankizumab (IL-23)Infusions at weeks 0, 4 and 8, maintenance from week 12Week 12 (ADVANCE, MOTIVATE)45% versus 25% clinical remission (ADVANCE)No week cut-off found
Guselkumab (IL-23)Infusions at weeks 0, 4 and 8, maintenance from week 12 or 16Week 12 (GALAXI-1, phase 2)57.4% versus 16.4% clinical remission on the best-performing induction armNo week cut-off found

The infliximab, vedolizumab, risankizumab, ustekinumab and guselkumab schedules come from the US labels (Entyvio, Skyrizi, Stelara, Tremfya, Remicade); the adalimumab schedule is from the CLASSIC I trial. These are US labels and schedules can differ in the UK, Canada and Australia, so check your own clinic letter. Trial numbers are not head-to-head: the drugs were tested in different populations, some of whom had already failed other biologics, with different scoring methods, so the columns cannot be ranked against each other. If you have not chosen yet, which biologic is best for Crohn's disease? compares the classes and what guidelines say.

Which Crohn's biologic works fastest?

There is no head-to-head trial that answers this, so the honest answer is that anti-TNF drugs look fastest in the published early timepoints, while newer interleukin drugs are typically judged at week 12. In ACCENT I, 58% responded within 2 weeks of a single infliximab infusion (Hanauer 2002). In CLASSIC I, remission at week 4 was 36% for the best adalimumab induction regimen versus 12% on placebo (Hanauer 2006).

Those early readouts do not mean anti-TNF drugs are better. They mean the trials looked early. The risankizumab and guselkumab trials only report a week-12 answer, so we cannot say how many people were in remission at week 4, and anyone quoting a precise figure is probably guessing. The ustekinumab trials were scored at week 6 (Feagan 2016), and the vedolizumab trial separated from placebo on remission at week 6 but not on the broader response measure (Sandborn 2013).

Speed also is not the same as effectiveness for you. The American Gastroenterological Association's 2025 living guideline groups infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab and upadacitinib as recommended over no treatment in moderate-to-severe Crohn's, with vedolizumab and certolizumab pegol suggested, and its tiers are about efficacy rather than speed (Scott 2025). Your drug is chosen for your disease location, behavior, prior treatments and other conditions. If you are wondering whether you are on the "right" one, that conversation belongs with your IBD team, and our guide to what to expect at your first biologic infusion covers the practicalities of the first doses.

How long does Entyvio (vedolizumab) take to work for Crohn's?

Vedolizumab is widely described as a slow starter, and the data fit that description loosely. In GEMINI 2, 14.5% on vedolizumab were in clinical remission at week 6 versus 6.8% on placebo, but the broader CDAI-100 response rate did not differ significantly (31.4% versus 25.7%) (Sandborn 2013). The US label says to discontinue in patients who show no evidence of therapeutic benefit by week 14 (Entyvio label).

Two honest caveats. First, GEMINI 2 reported its primary answer at week 6, so it tells us the early picture but not how many people benefit by week 14 or beyond, and we could not find a verified time-to-response figure beyond that. Second, the maintenance part of the trial only included people who had responded to induction: among those, 39.0% on dosing every 8 weeks were in remission at week 52 versus 21.6% on placebo. In r/CrohnsDisease, people on vedolizumab commonly describe waiting months before feeling a difference. That is an experience, not a rule, and the label's week-14 reference is a prescriber's checkpoint, not a patient's cue to stop. If you are on it and nothing has changed, take your log to your team and ask what they plan to review at that point.

How long do Skyrizi, Stelara and Tremfya take to work for Crohn's?

The interleukin drugs are judged at week 6 (ustekinumab) or week 12 (risankizumab, guselkumab). In ADVANCE, 45% of people on the lower risankizumab induction dose were in clinical remission by CDAI at week 12 versus 25% on placebo, and 40% had an endoscopic response versus 12% (D'Haens 2022). In the phase 2 guselkumab study, 57.4% on the best-performing induction arm were in remission at week 12 versus 16.4% on placebo (Sandborn 2022).

For ustekinumab, response at week 6 was 34.3% versus 21.5% in people who had failed anti-TNF drugs, and 51.7% versus 28.7% in people who had not (Feagan 2016). By week 44, 53.1% of those who had responded and then continued every 8 weeks were in remission versus 35.9% on placebo.

Several people in the Crohn's threads describe improvement within days or a few weeks on Skyrizi or Rinvoq, and others describe three to four months. Both fit the trial picture, in which a good share of people respond early, but the formal answer comes at week 12. Upadacitinib (Rinvoq) is an oral JAK inhibitor, not a biologic, and its trials used a 12-week induction: clinical remission was 49.5% versus 29.1% in U-EXCEL and 38.9% versus 21.1% in U-EXCEED (Loftus 2023).

What counts as response, remission and endoscopic healing?

Response means your symptoms improved by a set amount. Remission means they fell below a threshold. Endoscopic response or healing means the bowel lining looks better on a scope. Trials usually define clinical response as a fall of at least 100 points on the Crohn's Disease Activity Index (CDAI) or a score under 150, and clinical remission as a CDAI under 150 (Feagan 2016). Newer trials also use a patient-reported version based on average daily stool frequency and abdominal pain (D'Haens 2022).

TermWhat it means in trialsWhat it does not mean
Clinical responseA defined improvement, for example a CDAI fall of 100 points or moreYou are symptom-free
Clinical remissionCDAI under 150, or low scores for stool frequency and painThe bowel lining is healed
Biomarker responseFalling CRP or fecal calprotectinYour symptoms have gone
Endoscopic responseA drop of more than 50% in the SES-CD score on a scope (the upadacitinib trials' definition)The disease is gone

The international treat-to-target statements (STRIDE-II) set symptom relief and normalization of blood and fecal markers as short-term targets, and clinical remission and endoscopic healing as the long-term ones (Turner 2021). An update, STRIDE-III, was published online in October 2026. Its abstract says it defines treatment-specific times to target achievement and new fecal calprotectin thresholds (Turner 2026). We have not reproduced those numbers here because the full text was not available to verify them, so ask your team which timelines and cut-offs they use.

What do these numbers mean if the biologic is not working for me?

Not responding is a recognized outcome, not a personal failure. In the UK PANTS study of 1,610 people starting infliximab or adalimumab for the first time, primary non-response at week 14 occurred in 23.8% of the 1,241 assessable, and 63.1% were not in remission at week 54 (Kennedy 2019). Among 113 people who kept standard dosing after primary non-response, only 12.4% reached remission by week 54. That is one reason teams look closely at week 14.

PANTS also found that low drug concentration at week 14 was the only factor independently linked to primary non-response, which is why some clinics check drug levels around then. Our post on why you need blood tests on a biologic explains what those tests show. Response can also fade later: in the three-year follow-up, among those who initially responded, loss of response was estimated at 34.4% by year 1 and 60.0% by year 3 on infliximab (Chanchlani 2024). If that happens, our guide on what it means when a biologic stops working walks through the causes, and how often people switch biologics puts it in context.

Can symptoms improve while inflammation does not, or the reverse?

Yes, which is why "how do you feel?" is only half the check. In the CALM trial, treatment was escalated based on symptoms plus fecal calprotectin of 250 micrograms per gram or higher, CRP of 5 mg/L or higher, or recent prednisone use, and 46% of the tight-control group reached mucosal healing at week 48 versus 30% managed on symptoms alone (Colombel 2017). Symptoms alone missed inflammation in a meaningful share of people.

The reverse also happens. Some people have persistent bowel symptoms after inflammation has settled, such as an irritable-bowel-type overlay or damage from past disease. Our posts on whether fecal calprotectin can be normal in Crohn's and high calprotectin without symptoms cover both directions. The practical point is simple: your symptom log tells your team how you feel, and objective tests tell them what the bowel is doing. You need both.

Why do steroids matter while you wait for a biologic to work?

Steroids are sometimes used alongside a biologic to settle symptoms while the biologic takes effect, and that can muddy the picture. In CALM, for example, people had a course of prednisone induction before randomization, and recent prednisone use counted as treatment failure in the tight-control algorithm (Colombel 2017). In the Reddit threads, people describe both sides: steroids that carried them to the point where the biologic seemed to work, and symptoms returning when a taper felt too fast.

We are not going to tell you how to taper, and no thread should either, because the right plan depends on your dose, your disease and your risk of side effects. What you can do is record the dose and the date every time it changes, and note symptoms in the same weekly row. When your gastroenterologist asks "was that the biologic or the steroid?", the log is how you answer. If you are on a gut-targeted steroid such as budesonide, our guide on how long budesonide takes to work covers its separate timeline.

How can you log symptoms weekly to show your GI whether it is working?

A good log is short, consistent and dated against your treatment. Pick one day a week, fill in the same fields, and note every dose date, steroid change and test result. After 12 weeks you will have a table your team can read in a minute, which is far more useful than a memory of "a bit better lately".

What to recordHow oftenWhy it helps
Average stools per day, and how many were liquidDaily count, weekly averageStool frequency is a core component of the CDAI and patient-reported scores
Abdominal pain (0 to 3 or 0 to 10)Daily or weekly averageThe other core component of patient-reported remission
General wellbeingWeeklyA CDAI component, and the thing you care about most
Blood or mucus, urgencyAny day it happensShows trend and helps your team triage
Night-time bowel movementsCount per weekWaking at night is a flag for active disease
Steroid dose and date of each changeEvery changeSeparates biologic effect from steroid effect
Infusion or injection dates, any missed or late dosesEvery doseShows whether the schedule was followed
Calprotectin, CRP, hemoglobin, drug level resultsWhen resultedThe objective half of the picture
New symptoms (joint pain, mouth ulcers, fever, infection signs)When they appearSide effects and extra-intestinal signs matter

Weekly averages smooth out the daily noise that makes a single bad day feel like failure. Compare week 1 (your baseline before the first dose, if you have one) against weeks 4, 8, 12 and 14. If you do not have a baseline, start now and write a note saying so. Our guides on what to track in an IBD symptom diary, tracking symptoms during a flare and the symptom tracker to bring to your doctor go deeper on format.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

If you would rather not keep this on paper, Clairop lets you log stools, pain, blood, night-time episodes and medication in a few taps. For Crohn's it calculates a Harvey-Bradshaw Index from what you have logged and turns it into a one-page report with your score trend, medication adherence and lab results. It is a general wellness tool, not a diagnostic one, and it does not advise on medication. Its method page explains how it handles patterns. A spreadsheet works just as well if you will keep it up, and our roundup of apps for Crohn's disease compares the options.

When should you call your IBD team while waiting for a biologic to work?

Call promptly if you have any of these, rather than waiting for the next scheduled visit: blood in your stool that is new or increasing, a fever, severe or worsening abdominal pain, repeated vomiting, signs of dehydration, signs of infection, or symptoms of an allergic reaction after a dose. Seek urgent care for severe pain with a swollen abdomen, inability to keep fluids down, or feeling faint. Biologics lower some immune defences, so new infection symptoms deserve a call.

Beyond emergencies, contact your team if you reach the point your clinic gave you for review and your log shows no change, if symptoms clearly worsen over several weeks, or if you are relying on steroids to stay functional. Our guide on how to tell if you are in a Crohn's flare lists warning signs, and the questions to ask your doctor about Crohn's page helps you structure the visit. If the plan is changing and you want context, our posts on what to do when biologics fail and whether to start biologics for mild Crohn's explain the landscape, and the IBD symptom tracker app overview compares ways to keep the record.

What should you ask at your week 8 to 14 appointment?

Bring your weekly table and ask direct questions. Useful ones: What are we using to judge response (symptoms, calprotectin, CRP, a scan, a scope), and what result would count as working? When is the next assessment? Do my drug level or antibodies need checking? Should I expect to need a steroid, and what is the plan if my symptoms return as it comes down? If this drug is not doing enough, what are the options, and what would you want to see first? None of these ask your doctor to change anything. They ask the doctor to show you the plan. For a fuller checklist, see how to prepare for a GI appointment and the Remicade pros and cons post if you are on an infusion.

Common myths about biologic timelines

"If I do not feel better after the first dose, it is not working." Trials score after several doses, and some people take months. The first dose alone is rarely the whole story.

"Feeling better means the Crohn's is healed." Symptom response and endoscopic healing are different targets, which is why teams check calprotectin, CRP or a scan.

"If it has not worked by week 14, I should stop." The labels address prescribers, and the decision depends on your tests, drug level and symptoms. Do not stop or skip doses on your own.

"Newer drugs are always faster." The published early timepoints differ because the trials differ, not because one drug has been shown faster than another.

"Steroid improvement proves the biologic works." Steroids can settle symptoms on their own. Log both together.

The bottom line

Most Crohn's biologics need an induction course and several weeks before anyone can judge them, and the labels and trials point to roughly weeks 12 to 14 as the formal checkpoint. Some people improve sooner and some later. What helps most is being clear about what "working" means, tracking it weekly, and bringing that record to your gastroenterologist rather than guessing from a forum.

How this article was built. Trial figures come from the original papers, abstracts opened and checked. Drug schedules and week-14 wording come from the US prescribing labels via openFDA and DailyMed, effective dates in the sources list. Reddit threads are used for the questions people ask and how they describe their experience, never for medical facts. Where we could not verify a figure, such as a week-4 remission rate for the interleukin drugs or the STRIDE-III timelines, we say so.

This article is general information, not medical advice. Clairop is not affiliated with any drug manufacturer. Talk to your gastroenterologist or pharmacist about your own treatment.

Frequently asked questions

How long do biologics take to work for Crohn's disease?
It varies by drug and by person. Some people feel better within days or a few weeks, but trials score response and remission after the induction doses, commonly at weeks 6 to 12, and the infliximab and vedolizumab labels both refer to week 14. Your gastroenterologist decides when to judge your own response.
How long does Entyvio take to work for Crohn's disease?
Vedolizumab (Entyvio) is often described as a slow starter. In the GEMINI 2 trial, 14.5% of people on it were in remission at week 6 versus 6.8% on placebo, and the US label says to discontinue in patients who show no evidence of therapeutic benefit by week 14. Whether to continue is your prescriber's call.
How long does Skyrizi take to work for Crohn's disease?
In the ADVANCE and MOTIVATE trials, risankizumab (Skyrizi) was judged at week 12 after infusions at weeks 0, 4 and 8. In ADVANCE, 45% on the lower induction dose were in clinical remission by CDAI versus 25% on placebo. Some people report improvement sooner, but the trials do not give a firm earlier figure.
How long does Stelara take to work for Crohn's disease?
In the UNITI trials, ustekinumab (Stelara) was first judged at week 6, when clinical response was 34.3% versus 21.5% on placebo in people who had failed anti-TNF drugs, and 51.7% versus 28.7% in those who had not. The label schedules the first injection under the skin 8 weeks after the infusion.
How long do Humira and Remicade take to work for Crohn's?
Anti-TNF drugs are generally the fastest class in trials. In ACCENT I, 58% responded within 2 weeks of a single infliximab infusion, and in CLASSIC I, adalimumab remission at week 4 was 36% on the best induction regimen versus 12% on placebo. Even so, the UK PANTS study judged primary non-response at week 14.
What is the difference between clinical response and remission in Crohn's?
Response means symptoms improved by a set amount, for example a Crohn's Disease Activity Index (CDAI) drop of at least 100 points. Remission means symptoms fell below a threshold, such as a CDAI under 150. Endoscopic response or healing is a separate target that looks at the bowel lining rather than how you feel.
Can a biologic be working even if I feel no different?
Possibly, because symptoms and inflammation do not always move together. Treat-to-target guidance lists symptom relief plus normalization of blood and stool markers as short-term targets and endoscopic healing as a long-term one. Your team may use calprotectin, CRP or a scan alongside how you feel, so tell them how you feel and ask what they are measuring.
Should I stop my biologic if I do not feel better after a few doses?
Not on your own. Stopping or switching is a decision for your gastroenterologist, who will look at your symptoms, blood and stool markers, drug levels and sometimes imaging or a scope. Bring a dated symptom log and ask what the plan is at your next assessment point.
What is the best way to track whether my biologic is working?
Log the same few things on a fixed schedule: stool frequency, pain, general wellbeing, blood, night-time episodes, steroid use and dose dates, plus any calprotectin or CRP results. Clairop does this for Crohn's, calculating a Harvey-Bradshaw Index and producing a one-page report for your gastroenterologist. A paper table or spreadsheet works too, if you keep it consistent.
Do steroids hide whether a biologic is working?
They can. Steroids are often used to settle symptoms while a biologic takes effect, so improvement on both is hard to separate, and symptoms may return as the steroid is lowered. Log your steroid dose next to your symptoms and let your prescriber set any taper, never adjust it based on a forum thread.

Sources

  1. US National Library of Medicine. DailyMed: ENTYVIO (vedolizumab) prescribing information, set id 6e94621c-1a95-4af9-98d1-52b9e6f1949c, effective 29 April 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c
  2. US National Library of Medicine. DailyMed: REMICADE (infliximab) prescribing information, set id a0a046c1-056d-45a9-bfd9-13b47c24f257, effective 3 June 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257
  3. US National Library of Medicine. DailyMed: SKYRIZI (risankizumab-rzaa) prescribing information, set id 7148c8eb-b39e-e20a-6494-a6df82392858, effective 23 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858
  4. US National Library of Medicine. DailyMed: STELARA (ustekinumab) prescribing information, set id c77a9664-e3bb-4023-b400-127aa53bca2b, effective 8 September 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b
  5. US National Library of Medicine. DailyMed: TREMFYA (guselkumab) prescribing information, set id 1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56, effective 20 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56
  6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-9. doi:10.1016/S0140-6736(02)08512-4
  7. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-33. doi:10.1053/j.gastro.2005.11.030
  8. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65. doi:10.1053/j.gastro.2006.11.041
  9. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341-53. doi:10.1016/S2468-1253(19)30012-3
  10. Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9(6):521-38. doi:10.1016/S2468-1253(24)00044-X
  11. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-21. doi:10.1056/NEJMoa1215739
  12. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60. doi:10.1056/NEJMoa1602773
  13. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-30. doi:10.1016/S0140-6736(22)00467-6
  14. Sandborn WJ, D'Haens GR, Reinisch W, Panes J, Chan D, Gonzalez S, et al. Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-64. doi:10.1053/j.gastro.2022.01.047
  15. Loftus EV Jr, Panes J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023;388(21):1966-80. doi:10.1056/NEJMoa2212728
  16. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  17. Turner D, Vuyyuru SK, Ricciuto A, et al. Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD. Lancet Gastroenterol Hepatol. 2026 (published online 19 October 2026). doi:10.1016/S2468-1253(26)00292-X
  18. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-89. doi:10.1016/S0140-6736(17)32641-7
  19. Scott FI, Ananthakrishnan AN, Click B, Agrawal M, et al. AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe Crohn's disease. Gastroenterology. 2025;169(7):1397-448. doi:10.1053/j.gastro.2025.09.038

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools